Urinary MCP-1 levels were measured in 36 patients with OAB and 13 controls. Patients were treated after the first visit by different OAB treatments (anticholinergic, Beta-3 agonist and or, onabotulinum toxin A, neuromodulations). Urinary MCP-1 levels were measured by (ELISA). The urinary MCP-1 levels and OAB symptoms severity were compared at baseline, 1 month, and 3 months after treatments. Different validated OAB questionnaires were used.
The baseline urinary MCP-1 levels of patients with untreated OAB were significantly higher than that of controls with means. Urinary MCP-1 levels were significantly reduced at 3 months in 28 OAB-responders (77.8%). On other hand, 8 OAB- non-responders, showed unchanged in urinary MCP-1.The severity of OAB symptoms and QoL had significantly decreased with urinary MCP-1 levels OAB- responders at 1 and 3 months of OAB treatments.
They concluded that urinary MCP-1 levels were significantly higher in patients with OAB than in the controls. Patients with OAB who responded to treatments had significantly reduced urinary MCP-1 levels in association with a decreased severity of OAB symptoms at 3 months.
These promising findings could help understanding the pathophysiology of OAB and neurophysiological signaling in the bladder function, identification of a potential marker, and/or developing new drug targets for treatment of patients suffering from OAB.
Presenter by: Bilal Farhan MD
Authors: Bilal Farhan MD, Gamal Ghoniem MD FACS, Ahmed Ahmed MD and Frank Zaldivar MD PhD
University of California, Irvine, CA; UC, Irvine, CA
Written by: Bilal Farhan, MD, Female Urology Fellow and Voiding Dysfunction, Department of Urology, University of California, Irvine at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting (SUFU 2018), February 27-March 3, 2018, Austin, Texas